Clinical Trial Update: A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating JNJ-78278343, a T-cell–redirecting agent targeting KLK2, for advanced prostate cancer is currently listed as active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• JNJ-78278343

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING